Guardian Pharmacy Services, Inc.(GRDN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #720 of 2,961 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in GRDN
Events flagged as statistical outliers against GRDN's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
GRDN quality score jumped 22 points (47→70) on a new filing
View source filing →
GRDN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Guardian Pharmacy Services, Inc. (GRDN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRDN at 62.3/100 on a 32-signal composite quality model, placing it at rank #720 of 2,961 stocks — the top 25% of the AI-ranked universe. GRDN scores in the top quartile across balance sheet strength (94.3). Based on the latest XBRL financial filings (Q2 2026), Guardian Pharmacy Services, Inc. reports quarterly revenue of $351.8M, net income of $21.9M, an operating margin of 5.9%. Top institutional holders of GRDN by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, based on the most recent SEC filings. GRDN trades on the NYSE exchange and files with the SEC under CIK 1802255. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardian Pharmacy Services, Inc. directly from SEC EDGAR. Guardian Pharmacy Services, Inc.'s 13F Pro composite quality score has ranged between 62 and 70 since 2026, currently 62.3 — a declining long-term trajectory across 35 quarterly and live scoring snapshots.
What's Driving GRDN's Business? Latest 10-Q Breakdown
✓ 18/18 datapoints verifiedAI-extracted from Guardian Pharmacy Services, Inc.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew a modest 2.2% YoY to $351.8M as IRA-driven Medicare Part D price cuts offset acquisition and volume gains, while an $8.5M one-time legal settlement helped push net income to $22.1M.
Biggest Revenue Drivers
Incremental revenue contributed by pharmacy operations acquired during 2025
Decreased primarily due to Inflation Reduction Act Medicare Part D price reductions, despite residents served rising to ~210,000 and prescriptions dispensed rising to 7.6 million
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q2 2026
$351.8M
Net Income
Q2 2026
$21.9M
Operating Margin
Q2 2026
5.9%
ROIC
Q2 2026
32.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+17.9% YoYNet Income
+144.7% YoYOperating Income
+215.5% YoYTotal Assets
+28.6% YoYTotal Debt
Op. Cash Flow
+73.0% YoYFree Cash Flow
+100.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $1.45B +17.9% | $1.23B | — | — |
| Net Income | $49.2M +144.7% | $-110.0M | — | — |
| Operating Income | $72.7M +215.5% | $-62.9M | — | — |
| Total Assets | $412.7M +28.6% | $320.8M +18.3% | $271.2M | — |
| Total Debt | $0.00 | $0.00 -100.0% | $23.0M | — |
| Operating Cash Flow | $100.3M +73.0% | $58.0M | — | — |
| Free Cash Flow | $86.8M +100.8% | $43.3M | — | — |
Get alerted when GRDN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Guardian Pharmacy Services, Inc. including:
Top Institutional Holders of GRDN
FMR LLC
$135.7M3,241,612 shWELLINGTON MANAGEMENT GROUP LLP
$72.4M1,729,032 shBlackRock, Inc.
$66.0M1,575,989 shVANGUARD CAPITAL MANAGEMENT LLC
$57.8M1,379,750 shWoodline Partners LP
$54.7M1,306,340 shValiant Capital Management, L.P.
$49.7M1,186,658 shT. Rowe Price Investment Management, Inc.
$46.8M1,116,868 shBoston Partners
$40.8M983,868 shFRANKLIN RESOURCES INC
$40.5M966,206 shTimesSquare Capital Management, LLC
$39.8M951,637 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $135.7M | 3,241,612 |
| WELLINGTON MANAGEMENT GROUP LLP | $72.4M | 1,729,032 |
| BlackRock, Inc. | $66.0M | 1,575,989 |
| VANGUARD CAPITAL MANAGEMENT LLC | $57.8M | 1,379,750 |
| Woodline Partners LP | $54.7M | 1,306,340 |
| Valiant Capital Management, L.P. | $49.7M | 1,186,658 |
| T. Rowe Price Investment Management, Inc. | $46.8M | 1,116,868 |
| Boston Partners | $40.8M | 983,868 |
| FRANKLIN RESOURCES INC | $40.5M | 966,206 |
| TimesSquare Capital Management, LLC | $39.8M | 951,637 |
Companies Similar to GRDN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Pediatrix Medical Group, Inc.
ANI PHARMACEUTICALS INC
Pennant Group, Inc.
Concentra Group Holdings Parent, Inc.
Addus HomeCare Corp
LifeStance Health Group, Inc.
Aveanna Healthcare Holdings, Inc.
Encompass Health Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put GRDN on your watchlist
Track score changes the day Guardian Pharmacy Services, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GRDN a good stock to buy?
13F Pro's AI-powered analysis of Guardian Pharmacy Services, Inc. (GRDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRDN are available on the GRDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GRDN is classified as a mid company.
Which hedge funds own GRDN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Guardian Pharmacy Services, Inc.'s investment landscape.